HAVCR2 and acute myeloid leukemia: A current study has confirmed these findings by revealing a similar percentage of T cells in the BM microenvironment of AML patients and healthy donors, but a higher number of regulatory T (Treg) cells, PD-1-positive/OX40-positive T cells and PD-1-positive/CD8-positive T cells that also express TIM3 or LAG3 in the BM of AML patients [55].